Kolexia
Goncalves Anthony Oncologie médicale
Goncalves Anthony
Oncologie médicale
Centre Paoli-Calmettes
Marseille, France
577 Activités
923 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Métastase tumorale Tumeurs du sein triple-négatives Tumeurs du cerveau Récidive tumorale locale Carcinomes Cancers du sein inflammatoires Tumeur du sein de l'homme Cellules tumorales circulantes

Collaborateurs

Voir plus
Bertucci Francois
Bertucci Francois
Centre Paoli-Calmettes, Marseille, France
Dalenc Florence
Dalenc Florence
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
Ferrero Jean Marc
Ferrero Jean Marc
Centre Antoine Lacassagne, Nice, France
Bachelot Thomas
Bachelot Thomas
Centre Léon-Bérard, Lyon, France

Industries

Voir plus
CanceroDigest
3 collaboration(s)
Dernière en 2021
MSD
2 collaboration(s)
Dernière en 2021
AstraZeneca
2 collaboration(s)
Dernière en 2023
Novartis
1 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
CHANCES: A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors
Essai Clinique (Innate Pharma)   19 mars 2024
REPARP: Prospective and Multicentric Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.
Essai Clinique (Artios Pharma Ltd)   26 février 2024
MOST plus: A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Essai Clinique (Centre Léon-Bérard)   09 février 2024
Neoadjuvant chemotherapy for breast cancer: Pathologic response rates but not tumor size, has an independent prognostic impact on survival.
Cancer medicine   07 février 2024
Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data.
Breast (Edinburgh, Scotland)   22 décembre 2023
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
Breast cancer research and treatment   19 décembre 2023
Triple-negative and Her2-positive breast cancer in women aged 70 and over: prognostic impact of age according to treatment.
Frontiers in oncology   15 décembre 2023
Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
Nature communications   12 décembre 2023
21P Mass cytometry reveals a population of exhausted CD8+ T cells associated with durvalumab/tremelimumab/vinorelbine efficacy in advanced cervical cancer (iMOVIE)
Abstract Book of the ESMO Immuno-Oncology Congress 2023 6-8 December 2023   01 décembre 2023
SAFIR 03: A ctDNA Screening Program in Patients With HR+, HER2- Metastatic Breast Cancer for Detection of High-risk Relapse Patients on Any CDK4/6 Inhibitor and a Randomised Phase II Study Comparing Alpelisib Combined With Fulvestrant to Ribociclib Combined With Fulvestrant, in Patients With Persistent Targetable PIK3CA Mutations
Essai Clinique (Unicancer)   20 novembre 2023